Medexus Schedules First Fiscal Quarter 2024 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 10, 2023 to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on August 9, 2023. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and U.S. callers...
2023-08-02 7:00 AM EDT
Medexus Announces Preliminary Revenue for Fiscal Q1 2024
Ontario and Chicago, Illinois--(Newsfile Corp. - July 12, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company's fiscal quarter ended June 30, 2023 (the company's fiscal Q1 2024). All dollar amounts in this news release are in US dollars unless specified otherwise. Preliminary revenue estimates for fiscal Q1 2024 The expected results discussed in this news release are preliminary estimates, as Medexus's financial...
2023-07-12 5:30 PM EDT
Medexus Generates Record Revenue of US$108.1 Million in Fiscal Year 2023
Ontario and Chicago, Illinois--(Newsfile Corp. - June 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2023 (the company's fiscal Q4 2023 and fiscal year 2023). All dollar amounts in this press release are in United States dollars unless specified otherwise. Financial highlights Record total revenue of $108.1 million in fiscal...
2023-06-21 5:40 PM EDT
FDA Accepts for Review Medexus's IXINITY Supplemental Biological License Application for Pediatric Patients
Ontario and Chicago, Illinois--(Newsfile Corp. - June 15, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently accepted for review Medexus's supplemental Biological License Application (sBLA) for IXINITY® [coagulation factor IX (recombinant)] for the on-demand, prophylactic, and perioperative treatment of pediatric patients under 12 years of age with hemophilia B - a hereditary bleeding disorder characterized by a...
2023-06-15 7:25 AM EDT
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2023 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 14, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 22, 2023 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on June 21, 2023. To participate in the call, please dial the following numbers: 888-506-0062 (toll-free) for Canadian and...
2023-06-14 5:30 PM EDT
Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023
Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive...
2023-06-13 7:25 AM EDT
Medexus to Participate in the LD Micro Invitational XIII
Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the LD Micro Invitational XIII from June 6-8 2023. Event: LD Micro Invitational XIII Date: June 6-8, 2023 Location: Luxe Sunset Boulevard Hotel, California Medexus Presentation: Tuesday, June 6 at 2:30 PM Pacific time Ken d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief...
2023-06-01 5:30 PM EDT
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures
Ontario and Chicago, Illinois--(Newsfile Corp. - May 10, 2023) - Medexus Pharmaceuticals (TSX: MDP) (TSX: MDP.DB) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its 6% unsecured convertible debentures due 2023 (TSX: MDP.DB). Under the NCIB, Medexus may purchase for cancellation
2023-05-10 5:30 PM EDT
Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma
Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today presented data demonstrating a 33% cost savings with Gleolan® (aminolevulinic acid HCl) oral solution, compared to conventional white light surgery, in US patients with high-grade glioma. The data were presented at ISPOR 2023, the annual meeting of the Professional Society for Health Economics and Outcomes Research (formerly known as the International Society for...
2023-05-09 6:21 PM EDT